Coronavirus

Sotrovimab found not inferior to intravenous administration for the early treatment of mild-to-moderate COVID-19 in high-risk, non-hospitalized patients 12 years of age and older.

Non-classical monocytes, a type of innate immune cell that signals molecule to alert other immune cells to threats, could be potential target for COVID-19 therapies.

The model could help researchers and public health officials interpret the significance of existing variants and design tailored public health responses for various scenarios based on a variant’s characteristic.

The results showed that one 300 mg dose of AZD7442 reduced the risk of developing symptomatic COVID-19 by 83% and one 600 mg dose reduced the risk of developing severe COVID-19 or death (from any cause) by 88% compared to the placebo.

Among participants who had been infected with SARS-CoV-2, heart rate was reduced during physical exertion, and recovery was delayed after the exertion.

The analysis found that vaccination rates increased from 36% to 60% between January 2021 and April 2021 but then slowed, reaching just 70% as of September 2021.

Under the agreement, the government would acquire 10 million treatment courses to be delivered by Pfizer beginning later this year and concluding in 2022.

Rita Wise, DEd, MSN, RN, program director of the Masters in Nursing Education and Nursing Administration programs at Pennsylvania College of Health Sciences, discusses her hopes for how the country and health systems will respond to the national nurse staffing crisis.

However, many say that they would reconsider if local COVID-19 cases begin to spike at their destination, poll results show.

This follows the FDA’s decision to expand the emergency use authorization for Pfizer and Moderna booster vaccines to all individuals 18 and older.

The CDC Advisory Committee on Immunization Practices voted to recommend the use of a booster dose of the Moderna COVID-19 vaccine.

The Pfizer COVID-19 vaccine booster dose is the same strength as the primary series of the Pfizer COVID-19 vaccine, with findings demonstrating the same level of safety as the primary series.

A survey of caregivers and parents of children with cancer shows that nearly one-third expressed hesitancy to vaccinate their youngsters against COVID-19.

The difference in COVID-19 infection time between patients receiving heparin and those who did not was approximately 4 days on average.

Study finds COVID-19 booster shot was extremely beneficial for all patients with cancer, especially those with a blood cancer.

Their statement also calls upon the business community to support the new federal requirement that individuals working for companies with more than 100 employees be vaccinated.

After 6 to 7 months, just 8 individuals contracted proven symptomatic SARS-CoV-2 infection with rapid favorable evolution, study results show.

Molnupiravir (Lagevrio) is a potent ribonucleoside analog that blocks SARS-CoV-2 replication by acting as a competitive substrate of virally-encoded RNA-dependent RNA polymerase.

Pharmacists are at the forefront of not only providing COVID-19 vaccinations, but also the information a patient needs before receiving the vaccine

The time is now for pharmacists to do some initial checks and pre-holiday planning to make sure they are ready for the coming weeks.

Study results show that the type of vaccine patients received was a major factor in inducing an immune response, with those receiving mRNA shots faring better.

CMS Interim Final Rule on mandatory COVID-19 vaccinations for all facilities participating in Medicare and Medicaid potentially impacts pharmacies that provide services under a contract or arrangement with these facilities.

If authorized, ritonavir could be prescribed broadly as an at-home treatment to help reduce COVID-19 severity, hospitalizations, and deaths, as well as to reduce the probability of infection following exposure among adults.

Trends to watch include increased spending on drugs and treatments, expansion of pharmacists' role, and ongoing interest in home infusion therapy.

Study results show that those with lymphoproliferative disorders are the most likely to develop the virus after vaccination.

Parents or legal guardians of children in this age range are now able to schedule appointments for vaccination.

A single 1200 mg subcutaneous dose of casirivimab and imdevimab (Regen-COV, Regeneron Pharmaceuticals), a preventative COVID-19 treatment, reduced the risk of contracting COVID-19 by 81.6% during months 2-8, according to additional results from a phase 3 trial published in The New England Journal of Medicine.

The company plans to submit data to the European Medicines Agency, FDA, and other global regulators.

Structural changes to the COVID-19 virus highlight the need to expand the research efforts.